Nathan Bhatt

Nathan Bhatt has investigated immunotherapy plus antiangiogenic combinations for hepatocellular carcinoma, where the IMbrave150 trial established atezolizumab plus bevacizumab as the new first-line standard of care supplanting sorafenib. His research has examined the immunologic mechanisms supporting IO+VEGF synergy in HCC, including VEGF-mediated immunosuppression through myeloid cells and T regulatory cells in the hepatic immune environment. He has studied subsequent IO combination data in HCC including tremelimumab plus durvalumab from the HIMALAYA trial and sintilimab plus bevacizumab biosimilar in Asian populations, comparing response rates and survival outcomes across these regimens. His translational work on immune cell composition and checkpoint expression in HCC tumor microenvironments has contributed to understanding differential responses to IO monotherapy versus IO+VEGF combination in liver cancer.